Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NTRA
stocks logo

NTRA

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
473.16M
+14.47%
--
--
496.93M
+13%
--
--
519.13M
+9.05%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Natera, Inc. (NTRA) for FY2025, with the revenue forecasts being adjusted by 3.69% over the past three months. During the same period, the stock price has changed by 11.72%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.69%
In Past 3 Month
Stock Price
Go Up
up Image
+11.72%
In Past 3 Month
11 Analyst Rating
up Image0
Wall Street analysts forecast NTRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRA is 206.40 USD with a low forecast of 185.00 USD and a high forecast of 251.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 171.860
sliders
Low
185.00
Averages
206.40
High
251.00
up Image0
Current: 171.860
sliders
Low
185.00
Averages
206.40
High
251.00
Piper Sandler
Overweight
maintain
$205 -> $210
2025-05-15
Reason
Piper Sandler
Price Target
$205 -> $210
2025-05-15
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Natera to $210 from $205 following quarterly results. The firm keeps an Overweight rating on the shares.
Barclays
NULL -> Overweight
upgrade
$160 -> $190
2025-05-09
Reason
Barclays
Price Target
$160 -> $190
2025-05-09
upgrade
NULL -> Overweight
Reason
Barclays raised the firm's price target on Natera to $190 from $160 and keeps an Overweight rating on the shares. The firm updated the company's model post the earnings report.
BTIG
Buy
maintain
$190 -> $195
2025-05-09
Reason
BTIG
Price Target
$190 -> $195
2025-05-09
maintain
Buy
Reason
BTIG raised the firm's price target on Natera to $195 from $190 and keeps a Buy rating on the shares. The company delivered a strong Q1 earnings beat and raise, and Q1 was highlighted by record unit growth on a sequential basis in its Signatera MRD business, the analyst tells investors in a research note. Natera's drivers - robust volume growth across products, opportunities for average selling price expansion, new test offerings, and significant upside potential from updated guideline bodies - remain intact, the firm adds.
UBS
Dan Leonard
Buy
maintain
$211 -> $218
2025-05-09
Reason
UBS
Dan Leonard
Price Target
$211 -> $218
2025-05-09
maintain
Buy
Reason
UBS analyst Dan Leonard raised the firm's price target on Natera to $218 from $211 and keeps a Buy rating on the shares.
TD Cowen
Dan Brennan
Buy
maintain
$195 -> $200
2025-05-09
Reason
TD Cowen
Dan Brennan
Price Target
$195 -> $200
2025-05-09
maintain
Buy
Reason
TD Cowen analyst Dan Brennan raised the firm's price target on Natera to $200 from $195 and keeps a Buy rating on the shares after the company posted what the analyst calls "another solid result." In light of nervousness into Q1 given some peers' weather-induced volume issues, Signatera's 52% year-over-year growth "should be well-received," the analyst tells investors.
Barclays
Luke Sergott
Buy
Maintains
$200 → $160
2025-04-10
Reason
Barclays
Luke Sergott
Price Target
$200 → $160
2025-04-10
Maintains
Buy
Reason
Barclays lowered the firm's price target on Natera to $160 from $200 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Natera Inc (NTRA.O) is -75.19, compared to its 5-year average forward P/E of -31.26. For a more detailed relative valuation and DCF analysis to assess Natera Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-31.26
Current PE
-75.19
Overvalued PE
-4.51
Undervalued PE
-58.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-32.04
Current EV/EBITDA
-76.60
Overvalued EV/EBITDA
-4.04
Undervalued EV/EBITDA
-60.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
9.24
Current PS
10.94
Overvalued PS
13.50
Undervalued PS
4.99

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 265.72% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

NTRA News & Events

Events Timeline

(ET)
2025-06-04
07:32:49
Natera announces Medicare coverage for Signatera MRD assay
select
2025-05-08 (ET)
2025-05-08
16:46:44
Natera raises FY25 revenue view to $1.94B-$2.02B, consensus $1.92B
select
2025-05-08
16:45:46
Natera reports Q1 EPS (50c), consensus (66c)
select
Sign Up For More Events
Sign Up For More Events

News

Preview
3.0
06-13NASDAQ.COM
Guru Fundamental Report for NTRA

  • Natera Inc. Analysis: Natera Inc. (NTRA) has received a 66% rating using the P/B Growth Investor model by Partha Mohanram, indicating potential for sustained future growth in the Biotechnology & Drugs industry.

  • Partha Mohanram's Contribution: Partha Mohanram, an academic and expert in value investing, developed a growth model that challenges traditional views on growth investing, focusing on financial statement analysis to identify successful growth stocks.

Preview
5.0
06-12NASDAQ.COM
Insider Sale: Director at $NTRA Sells 3,400 Shares

  • Insider Trading Activity: Gail Boxer Marcus, a director at $NTRA, sold 3,400 shares for approximately $558,733, representing about 35% of her holdings, while insiders have conducted 225 sales with no purchases in the past six months.

  • Institutional and Analyst Insights: In the last quarter, 345 institutional investors increased their positions in $NTRA, while analysts issued two buy ratings and no sell ratings on the stock.

Preview
4.5
06-09NASDAQ.COM
Noteworthy ETF Inflows: XBI, EXAS, NBIX, NTRA

  • XBI Share Price Analysis: The XBI ETF has a 52-week low of $66.66 and a high of $105.47, with the latest trade at $84.09, indicating its current position within this range.

  • ETF Trading Dynamics: ETFs function like stocks but involve trading "units" that can be created or destroyed based on investor demand, affecting the underlying holdings and market flows.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Natera Inc (NTRA) stock price today?

The current price of NTRA is 171.86 USD — it has increased 0.51 % in the last trading day.

arrow icon

What is Natera Inc (NTRA)'s business?

Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.

arrow icon

What is the price predicton of NTRA Stock?

Wall Street analysts forecast NTRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRA is 206.40 USD with a low forecast of 185.00 USD and a high forecast of 251.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Natera Inc (NTRA)'s revenue for the last quarter?

Natera Inc revenue for the last quarter amounts to 501.83M USD, increased 36.46 % YoY.

arrow icon

What is Natera Inc (NTRA)'s earnings per share (EPS) for the last quarter?

Natera Inc. EPS for the last quarter amounts to -0.50 USD, decreased -10.71 % YoY.

arrow icon

What changes have occurred in the market's expectations for Natera Inc (NTRA)'s fundamentals?

The market is revising Upward the revenue expectations for Natera, Inc. (NTRA) for FY2025, with the revenue forecasts being adjusted by 3.69% over the past three months. During the same period, the stock price has changed by 11.72%.
arrow icon

How many employees does Natera Inc (NTRA). have?

Natera Inc (NTRA) has 4424 emplpoyees as of June 23 2025.

arrow icon

What is Natera Inc (NTRA) market cap?

Today NTRA has the market capitalization of 23.47B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free